Mr. Michal Efraty reports

NEUROTHERA LABS GRANTED JAPANESE PATENT FOR ITS PROPRIETARY, INNOVATIVE THERAPEUTIC COMBINATION

Neurothera Labs Inc. has been granted a patent by Japanese Patent Office for its pharmacological combination titled "Compositions and Methods for Potentiating Derivatives of 4-Aminophenols."

The newly granted Japanese patent covers pharmaceutical compositions and methods comprising proprietary combinations of 4-aminophenols derivatives (including paracetamol) and N-acylethanolamines. These combinations are designed to enhance the analgesic and antipyretic performance of 4-aminophenol-based therapies. Neurothera believes this synergistic approach may enable lower effective dosing while helping to mitigate dose-related side-effect concerns associated with established treatments.

This patent further strengthens Neurothera's expanding intellectual property portfolio reinforcing protection for its combination-therapy platforms designed to optimize and modernize standard treatments for pain, fever and related conditions.

The addition of Japanese patent coverage marks an important strategic milestone as the Company advances its next-generation therapeutic innovations across global markets.

Neurothera Labs continues to advance its therapeutic platforms with the goal of delivering safe, effective and accessible treatments to patients worldwide.

About Neurothera Labs Inc.

Neurothera is a clinical-stage pharmaceutical company focused on developing novel therapeutics for central nervous system disorders and other underserved health conditions through collaborations and innovative combinations.

We seek Safe Harbor.